Ulrike Ulbricht
About
In The Last Decade
Ulrike Ulbricht
8 papers receiving 840 citations
Peers
Comparison fields: 5 of 55
- Molecular Biology 546
- Cancer Research 297
- Genetics 293
- Oncology 162
- Cell Biology 137
Countries citing papers authored by Ulrike Ulbricht
This map shows the geographic impact of Ulrike Ulbricht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Ulbricht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Ulbricht more than expected).
Fields of papers citing papers by Ulrike Ulbricht
This network shows the impact of papers produced by Ulrike Ulbricht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Ulbricht. The network helps show where Ulrike Ulbricht may publish in the future.
Co-authorship network of co-authors of Ulrike Ulbricht
This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Ulbricht. A scholar is included among the top collaborators of Ulrike Ulbricht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Ulbricht. Ulrike Ulbricht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 62 | |
| 3 | 26 | |
| 4 | 100 | |
| 5 | 104 | |
| 6 | 71 | |
| 7 | Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. | 147 |
| 8 | Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. | 342 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.